A 58-year-old male smoker presents with a 3-month history of progressive dyspnea, chest pain, and hemoptysis. Chest X-ray shows a central hilar mass with mediastinal widening. Bronchoscopic biopsy confirms small cell lung cancer (SCLC) with extensive stage disease. Which is the drug of choice for first-line chemotherapy in this patient?

Explanation

## First-Line Chemotherapy for Small Cell Lung Cancer **Key Point:** Cisplatin + Etoposide (PE) is the gold-standard first-line regimen for both limited-stage and extensive-stage SCLC, established by decades of clinical trial evidence and international guidelines. ### Mechanism of Action - **Cisplatin**: Platinum-based alkylating agent; forms DNA cross-links, induces apoptosis - **Etoposide**: Topoisomerase II inhibitor; prevents DNA religation, causes double-strand breaks ### Why PE is Preferred in SCLC | Feature | Cisplatin + Etoposide | Carboplatin + Etoposide | Other Regimens | |---------|----------------------|------------------------|----------------| | **Response Rate** | 60–80% (extensive stage) | 55–70% (similar efficacy) | Lower (taxanes, gemcitabine) | | **Survival Benefit** | Proven OS benefit | Equivalent, less nephrotoxic | Not established as 1st-line | | **Standard of Care** | Yes (NCCN, ESMO, ASCO) | Alternative if renal impairment | Salvage/relapsed disease | | **Toxicity Profile** | Nephrotoxicity, ototoxicity | Better renal tolerance | Variable | **High-Yield:** PE chemotherapy is typically given as 4–6 cycles (21-day intervals). Concurrent thoracic radiotherapy is added in limited-stage disease; extensive-stage disease receives chemotherapy alone unless performance status permits. **Clinical Pearl:** Carboplatin + Etoposide is an acceptable alternative when cisplatin is contraindicated (e.g., baseline renal impairment, significant hearing loss), but cisplatin-based therapy remains the preferred choice if tolerated [cite:Harrison 21e Ch 101]. ### Treatment Algorithm ```mermaid flowchart TD A[Small Cell Lung Cancer Diagnosed]:::outcome --> B{Staging}:::decision B -->|Limited Stage| C[Cisplatin + Etoposide + Concurrent TRT]:::action B -->|Extensive Stage| D[Cisplatin + Etoposide x 4-6 cycles]:::action D --> E{Cisplatin Contraindicated?}:::decision E -->|No| F[Continue PE]:::action E -->|Yes| G[Carboplatin + Etoposide]:::action F --> H[Assess Response]:::outcome G --> H ``` **Mnemonic:** **PE-SCLC** = **P**latin (Cisplatin) + **E**toposide for **SCLC** — the backbone regimen.